In addition, it was found that, among NSCLC patients treated with anti-PD-1 antibodies, lower ATF-3 and PD-L1 expression in tumor tissues from non-responder patients was shown (Liu et al., 2020). This evidence concerns the gene ATF3 and non-small cell lung carcinoma.